These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Stuck in the middle: Huntington's disease or not Huntington's disease? Ziso B; Larner AJ; Alusi SH J Neuropsychiatry Clin Neurosci; 2015; 27(1):e85-6. PubMed ID: 25716512 [No Abstract] [Full Text] [Related]
6. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Li SH; Li XJ Trends Genet; 2004 Mar; 20(3):146-54. PubMed ID: 15036808 [TBL] [Abstract][Full Text] [Related]
7. The therapeutic potential of G-protein coupled receptors in Huntington's disease. Dowie MJ; Scotter EL; Molinari E; Glass M Pharmacol Ther; 2010 Nov; 128(2):305-23. PubMed ID: 20708032 [TBL] [Abstract][Full Text] [Related]
9. Weight loss in Huntington disease increases with higher CAG repeat number. Aziz NA; van der Burg JM; Landwehrmeyer GB; Brundin P; Stijnen T; ; Roos RA Neurology; 2008 Nov; 71(19):1506-13. PubMed ID: 18981372 [TBL] [Abstract][Full Text] [Related]
10. Cellular localization of huntingtin in striatal and cortical neurons in rats: lack of correlation with neuronal vulnerability in Huntington's disease. Fusco FR; Chen Q; Lamoreaux WJ; Figueredo-Cardenas G; Jiao Y; Coffman JA; Surmeier DJ; Honig MG; Carlock LR; Reiner A J Neurosci; 1999 Feb; 19(4):1189-202. PubMed ID: 9952397 [TBL] [Abstract][Full Text] [Related]
11. Juvenile Huntington's disease: does a dosage-effect pathogenic mechanism differ from the classical adult disease? Squitieri F; Frati L; Ciarmiello A; Lastoria S; Quarrell O Mech Ageing Dev; 2006 Feb; 127(2):208-12. PubMed ID: 16274727 [TBL] [Abstract][Full Text] [Related]
12. Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies. Borrell-Pagès M; Zala D; Humbert S; Saudou F Cell Mol Life Sci; 2006 Nov; 63(22):2642-60. PubMed ID: 17041811 [TBL] [Abstract][Full Text] [Related]
13. Animal models of Huntington's disease: implications in uncovering pathogenic mechanisms and developing therapies. Wang LH; Qin ZH Acta Pharmacol Sin; 2006 Oct; 27(10):1287-302. PubMed ID: 17007735 [TBL] [Abstract][Full Text] [Related]
15. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Arrasate M; Mitra S; Schweitzer ES; Segal MR; Finkbeiner S Nature; 2004 Oct; 431(7010):805-10. PubMed ID: 15483602 [TBL] [Abstract][Full Text] [Related]
16. Hypothesis: Huntingtin may function in membrane association and vesicular trafficking. Truant R; Atwal R; Burtnik A Biochem Cell Biol; 2006 Dec; 84(6):912-7. PubMed ID: 17215878 [TBL] [Abstract][Full Text] [Related]
17. Huntington's Disease: Mechanisms of Pathogenesis and Therapeutic Strategies. Jimenez-Sanchez M; Licitra F; Underwood BR; Rubinsztein DC Cold Spring Harb Perspect Med; 2017 Jul; 7(7):. PubMed ID: 27940602 [TBL] [Abstract][Full Text] [Related]
18. Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease. Weiss A; Klein C; Woodman B; Sathasivam K; Bibel M; Régulier E; Bates GP; Paganetti P J Neurochem; 2008 Feb; 104(3):846-58. PubMed ID: 17986219 [TBL] [Abstract][Full Text] [Related]
19. Azadiradione Restores Protein Quality Control and Ameliorates the Disease Pathogenesis in a Mouse Model of Huntington's Disease. Singh BK; Vatsa N; Nelson VK; Kumar V; Kumar SS; Mandal SC; Pal M; Jana NR Mol Neurobiol; 2018 Aug; 55(8):6337-6346. PubMed ID: 29294248 [TBL] [Abstract][Full Text] [Related]